Optimal management of urosepsis from the urological perspective

被引:85
作者
Wagenlehner, Florian M. E. [1 ]
Weidner, Wolfgang
Naber, Kurt G.
机构
[1] Univ Giessen, Urol Clin, D-35390 Giessen, Germany
[2] Tech Univ Munich, D-8000 Munich, Germany
关键词
urinary tract infections; urosepsis; SIRS; sepsis therapy;
D O I
10.1016/j.ijantimicag.2007.06.027
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Urosepsis in adults comprises approximately 25% of all sepsis cases and in most cases is due to complicated urinary tract infections (UTIs). In this paper we review the optimal management of urosepsis from the urological point of view. Urosepsis is often due to obstructed uropathy of the upper or lower urinary tract. The treatment of urosepsis comprises four major aspects: 1. Early goal-directed therapy; 2. Optimal pharmacodynamic exposure to antimicrobials both in blood and in the urinary tract; 3. Control of complicating factors in the urinary tract; 4. Specific sepsis therapy. Early tissue oxygenation, appropriate initial antibiotic therapy and rapid identification and control of the septic focus in the urinary tract are critical steps in the successful management of a patient with severe urosepsis. To achieve this goal an optimal interdisciplinary approach encompassing the emergency unit, urological specialties and intensive-care medicine is necessary. (C) 2007 Elsevier B.V. and the International Society of Chemotherapy. All rights reserved.
引用
收藏
页码:390 / 397
页数:8
相关论文
共 63 条
  • [1] Host subversion by formation of intracellular bacterial communities in the urinary tract
    Anderson, GG
    Martin, SM
    Hultgren, SJ
    [J]. MICROBES AND INFECTION, 2004, 6 (12) : 1094 - 1101
  • [2] Ando E, 2004, ACTA MED OKAYAMA, V58, P207
  • [3] Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock
    Annane, D
    Sébille, V
    Charpentier, C
    Bollaert, PE
    François, B
    Korach, JM
    Capellier, G
    Cohen, Y
    Azoulay, E
    Troché, G
    Chaumet-Riffaut, P
    Bellissant, E
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2002, 288 (07): : 862 - 871
  • [4] Septic shock
    Astiz, ME
    Rackow, EC
    [J]. LANCET, 1998, 351 (9114) : 1501 - 1505
  • [5] Safety and dose relationship of recombinant human activated protein C for coagulopathy in severe sepsis
    Bernard, GR
    Ely, EW
    Wright, TJ
    Fraiz, J
    Stasek, JE
    Russell, JA
    Mayers, I
    Rosenfeld, BA
    Morris, PE
    Yan, SB
    Helterbrand, JD
    [J]. CRITICAL CARE MEDICINE, 2001, 29 (11) : 2051 - 2059
  • [6] Expression of cellulose and curli fimbriae by Escherichia coli isolated from the gastrointestinal tract
    Bokranz, W
    Wang, XD
    Tschäpe, H
    Römling, U
    [J]. JOURNAL OF MEDICAL MICROBIOLOGY, 2005, 54 (12) : 1171 - 1182
  • [7] DEFINITIONS FOR SEPSIS AND ORGAN FAILURE
    BONE, RC
    SPRUNG, CL
    SIBBALD, WJ
    [J]. CRITICAL CARE MEDICINE, 1992, 20 (06) : 724 - 726
  • [8] DEFINITIONS FOR SEPSIS AND ORGAN FAILURE AND GUIDELINES FOR THE USE OF INNOVATIVE THERAPIES IN SEPSIS
    BONE, RC
    BALK, RA
    CERRA, FB
    DELLINGER, RP
    FEIN, AM
    KNAUS, WA
    SCHEIN, RMH
    SIBBALD, WJ
    [J]. CHEST, 1992, 101 (06) : 1644 - 1655
  • [9] A European perspective on nosocomial urinary tract infections II.: Report on incidence, clinical characteristics and outcome (ESGNI-004 study)
    Bouza, E
    San Juan, R
    Muñoz, P
    Voss, A
    Kluytmans, J
    [J]. CLINICAL MICROBIOLOGY AND INFECTION, 2001, 7 (10) : 532 - 542
  • [10] EPISEPSIS: a reappraisal of the epidemiology and outcome of severe sepsis in French intensive care units
    Brun-Buisson, C
    Meshaka, P
    Pinton, P
    Vallet, B
    Rodie-Talbere, P
    Zahar, JR
    [J]. INTENSIVE CARE MEDICINE, 2004, 30 (04) : 580 - 588